Core Viewpoint - Anhui Zhongji Guoyi Medical Technology Co., Ltd. (referred to as "Guoyi Technology") has submitted a listing application to the Hong Kong Stock Exchange, aiming to capitalize on its position as a leader in China's third-party SPD (Supply, Processing, and Distribution) solutions market, with a market share of 29.2% as of 2024 [1][3]. Company Overview - SPD refers to an innovative supply chain model that optimizes the supply and management of medical materials in hospitals, addressing inefficiencies in traditional supply chain methods that rely heavily on manual operations and limited information sharing [3]. - Guoyi Technology's SPD solutions include three core components: SPD software systems, intelligent hardware, and professional services, which help hospitals reduce operational costs and improve supply management efficiency [3]. - As of September 30, 2025, Guoyi Technology's SPD solutions have been deployed in 116 hospitals across 13 provinces in China, including three of the eight A++ hospitals that have adopted SPD solutions [3]. Product Development - In addition to SPD solutions, Guoyi Technology has developed an in-hospital IDS (Intelligent Distribution System) solution based on IoT and AI technologies, set to launch in 2024 [4]. - The IDS solution will cover logistics for various materials in complex hospital environments, including medical consumables, pharmaceuticals, and medical waste, across critical operational areas such as operating rooms and pharmacies [4]. Financial Information - For the fiscal year ending December 31, 2023, Guoyi Technology reported revenues of approximately RMB 248.2 million, with projected revenues of RMB 377.9 million for 2024 [6]. - The gross profit for the same periods was RMB 92.0 million in 2023 and is expected to rise to RMB 158.2 million in 2024, indicating a gross margin increase from 37.1% to 41.8% [6][8]. - The net profit for the nine months ending September 30, 2024, is projected to be RMB 57.6 million, up from RMB 12.3 million in 2023 [7]. Industry Overview - The overall market for SPD solutions in China is projected to grow from RMB 18.4 billion in 2019 to RMB 181.5 billion by 2024, with a compound annual growth rate (CAGR) of 58.1% [9][10]. - The market for medical consumables through SPD solutions is expected to increase from RMB 15.9 billion in 2019 to RMB 151.3 billion by 2024, with a CAGR of 56.9% [9][10]. - The third-party SPD solutions market is anticipated to grow from RMB 1 billion in 2019 to RMB 11 billion by 2024, with a CAGR of 75.7% [12][13].
新股消息 | 国医科技递表港交所 为中国最大的第三方SPD解决方案提供商
智通财经网·2026-01-21 23:18